167 related articles for article (PubMed ID: 10673786)
1. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.
Souza PE; Mesquita RA; Gomez RS
Oral Dis; 2000 Jan; 6(1):35-9. PubMed ID: 10673786
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor.
de Souza PE; Paim JF; Carvalhais JN; Gomez RS
J Oral Pathol Med; 1999 Feb; 28(2):54-8. PubMed ID: 9950250
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G
Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341
[TBL] [Abstract][Full Text] [Related]
5. Immunoexpression of TNF-α and TGF-β in central and peripheral giant cell lesions of the jaws.
de Matos FR; de Moraes M; Nonaka CF; de Souza LB; de Almeida Freitas R
J Oral Pathol Med; 2012 Feb; 41(2):194-9. PubMed ID: 21913991
[TBL] [Abstract][Full Text] [Related]
6. Quantitative expression analysis of apoptotic/antiapoptotic genes and association with immunolocalization of BAX and BCL-2 in peripheral and central giant cell lesions of the jaws.
Amaral FR; Bernardes VF; Duarte AP; Pereira NB; Vasconcelos AC; Gomez RS; Gomes CC
Tumour Biol; 2011 Oct; 32(5):997-1003. PubMed ID: 21706237
[TBL] [Abstract][Full Text] [Related]
7. WWOX expression in giant cell lesions of the jaws.
Amaral FR; Diniz MG; Bernardes VF; Souza PE; Gomez RS; Gomes CC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Aug; 116(2):210-3. PubMed ID: 23849374
[TBL] [Abstract][Full Text] [Related]
8. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of RANKL in oral giant cell lesions is predictive of aggressiveness.
Martini G; Capella D; Rivero ERC; Gondak RO
Braz Oral Res; 2018 Oct; 32():e115. PubMed ID: 30379236
[TBL] [Abstract][Full Text] [Related]
10. NFATc1 and TNFalpha expression in giant cell lesions of the jaws.
Amaral FR; Brito JA; Perdigão PF; Carvalho VM; de Souza PE; Gomez MV; De Marco L; Gomez RS
J Oral Pathol Med; 2010 Mar; 39(3):269-74. PubMed ID: 20002873
[TBL] [Abstract][Full Text] [Related]
11. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
[TBL] [Abstract][Full Text] [Related]
12. FASN expression, angiogenesis and lymphangiogenesis in central and peripheral giant cell lesions.
Falci SG; Mesquita AT; Andrade BA; Miranda JL; Leon JE; Almeida OP; Santos CR
J Appl Oral Sci; 2014 Apr; 22(2):131-7. PubMed ID: 24676584
[TBL] [Abstract][Full Text] [Related]
13. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
14. Expressions of proliferation markers (Ki-67, proliferating cell nuclear antigen, and silver-staining nucleolar organizer regions) and of p53 tumor protein in gestational trophoblastic disease.
Kale A; Söylemez F; Ensari A
Am J Obstet Gynecol; 2001 Mar; 184(4):567-74. PubMed ID: 11262454
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors].
Berny W; Weiser A; Markowska-Woyciechowska A; Jarmundowicz W; Zub W; Załuski R
Neurol Neurochir Pol; 2004; 38(6):457-63. PubMed ID: 15654669
[TBL] [Abstract][Full Text] [Related]
16. Assessment of cellular proliferation of sebaceous neoplasms by AgNOR counts and immunohistochemical demonstrations of PCNA and Ki-67.
Ansai S; Koseki S; Hozumi Y; Kondo S; Aso K
J Dermatol; 1995 Apr; 22(4):238-48. PubMed ID: 7608380
[TBL] [Abstract][Full Text] [Related]
17. PCNA and Ki-67 immunoreactivity in multinucleated cells of giant cell fibroma and peripheral giant cell granuloma.
Mighell AJ; Robinson PA; Hume WJ
J Oral Pathol Med; 1996 May; 25(5):193-9. PubMed ID: 8835814
[TBL] [Abstract][Full Text] [Related]
18. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome.
Delahunt B; Bethwaite PB; Thornton A; Ribas JL
Cancer; 1995 Jun; 75(11):2714-9. PubMed ID: 7743475
[TBL] [Abstract][Full Text] [Related]
19. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct.
Suto T; Sugai T; Nakamura S; Funato O; Nitta H; Sasaki R; Kanno S; Saito K
Cancer; 1998 Jan; 82(1):86-95. PubMed ID: 9428483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
